Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers

ABSTRACT: Intervention1: Aspirin: 200 mg OD for 3 years Control Intervention1: Placebo: 200 mg OD for 3 years Primary outcome(s): 1. Disease free survival for all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer ptient sub groups)Timepoint: 3 years;Disease free survival for colon cancer (high risk Dukes B and Dukes C colon cancer)Timepoint: 3 years Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

DISEASE(S): Dukes C And High Risk Dukes B Colorectal Cancer

PROVIDER: 2572425 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Evaluating the effectiveness of Aspirin in Colorectal Cancer patients in terms of disease free survival and overall survival.

Project description:Interventions: An eligible subject will be randomised to the study in 1:1 ratio to either - Aspirin arm: 200 mg Aspirin once a day for 3 years - Placebo arm: 200 mg matching placebo once a day for 3 years. After randomisation, patient will have 3 monthly assessments for 3 years (month 3 to month 36) followed by 6 monthly assessments for additional 2 years (month 42 to month 60). Assessments include Haematology, Biochemistry, Colonoscopy, CT Scan, X-ray, ECG). Primary outcome(s): 1.Disease free survival (DFS) among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups) 2.DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer) [From randomization up to 5 years (3 monthly assessments for 3 years followed by 6 monthly assessments for additional 2 years)] Study Design: Randomized controlled trial

| 2564675 | ecrin-mdr-crc

A phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

Project description:Intervention1: Masitinib, FOLFIRI: Masitinib will be taken orally, daily at 6mg/kg/day. FOLFIRI will be administered every 2 weeks Control Intervention1: Placebo, FOLFIRI: Placebo will be taken orally, daily. FOLFIRI will be administered every 2 weeks Primary outcome(s): Overall Survival (OS)Timepoint: till death or last follow up Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant and Investigator Blinded

| 2577140 | ecrin-mdr-crc

Transcription profiling of 10 sample types: normal colon tissue, non cancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases, see also E-TIGR-14, E-TIGR-15

Project description:This study was designed to find patterns of gene expression in colon cancer samples that correlate with clinical stage. Ten samples were profiled from each of the following sample types: normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases. See also E-TIGR-14, E-TIGR-15

2005-01-01 | E-TIGR-14 | biostudies-arrayexpress

Transcription profiling of ten human samples of normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases

2005-01-01 | E-TIGR-15 | biostudies-arrayexpress

Transcription profiling of ten human samples of normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases

2005-01-01 | E-TIGR-16 | biostudies-arrayexpress

Evaluate the effect of Nutraceutical Product (Onconeem) in patients with Colorectal Cancer

Project description:Intervention1: Onconeem: Onconeem 100 mg capsules will be taken twice daily along with SOC (palliative chemotherapy /radiotherapy of investigators choice) for a duration of 84 days Control Intervention1: Onconeem matching placebo: The placebo will be taken twice daily along with SOC (e.g., palliative chemotherapy/radiotherapy of investigator choice) for a duration of 84 days Primary outcome(s): Improvement in Quality of life (measured using FACT-G questionnaire) from baseline till End of treatment (EOT)Timepoint: Day 84 Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Investigator Blinded

| 30959 | ecrin-mdr-crc

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

Project description:This was a phase II, randomized, placebo-controlled, double-blinded single center study (clinicaltrials.gov: NCT01806662) to investigate safety and efficacy of ustekinumab treatment in moderate-to-severe AD patients. Patients underwent 1:1 randomization using a computer generated subject randomization table by an unblinded pharmacist. to Subjects received subcutaneous ustekinumab or placebo at weeks 0, 4, and 16 with a crossover to the other agent (either ustekinumab or placebo) at weeks 16, 20, and 32 (Figure 1A) to ensure patient retention.

2019-11-20 | GSE140684 | GEO

A clinical trial to study the effects of two drugs, Folfox and CT-011 in patients with cancer of large intestine.

Project description:Intervention1: CT-011: CT-011 (Monoclonal Antibody), 3.0 mg/kg for days 0, 4, 8, 12, 24, 36, 48, 60, 76 along with the combination of FOLFOX . Dose Value; 3mg/kg (OD). Frequency: Every 2 weeks Route: Intravenous TOTAL duration of therapy: 32 months Control Intervention1: Chemotherapy regimens include FOLFOX4 or mFOLFOX6 (5-FU, oxaliplatin: Humanized monoclonal antibody. Treatment details similar as of Intervention. Primary outcome(s): The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone. [ Time Frame: 32 months ]Timepoint: Within 32months following the first CT-011 treatment Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2575782 | ecrin-mdr-crc

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Project description:We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally. STUDY OBJECTIVE To assess the effectiveness of Aspirin against placebo control in patients with dukes C or high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall Survival (OS) Primary endpoints * DFS among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups); * DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer). Secondary endpoints * Overall survival (OS) over 5 years * DFS and OS in * Chinese, Malay, Indian and other ethnic groups * Resected high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer sub-groups, individually * Compliant versus non-compliant subjects * PIK3CA mutated tumors (where samples are available)

| 2046934 | ecrin-mdr-crc

Benefits of a combination of chemotherapy tablets and injectable targeted therapy versus using a targeted therapy tablet alone in colorectal cancer patients

Project description:Intervention1: Arm A TAS-102 plus Bevacizumab: Bevacizumab 5 mg per m2 IV over 60 mins q every 15 days subsequent administrations over 30 mins if the initial administration tolerated well plus Tab TAS 102 35 mg per m2 twice daily on days 1to5 and 8 to 12 PO every 28 days 1 cycle Start of next cycle on D 29 Control Intervention1: Arm B Regorafenib: Tab Regorafenib 80 mg PO OD 3 weeks on 1 week off q 28 days 1 cycle Regorafenib dosing will be escalated by 40mg every cycle if there is no grade 3 or grade 4 Regorafenib related adverse events in the prior cycle Primary outcome(s): To evaluate the difference in overall survival (OS) at 6 months between TAS102-Bevacizumab combination and Regorafenib. Timepoint: 53 months Study Design: Other Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:On-site computer system Blinding and masking:Open Label

| 57245 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data